种族和族裔构成与成瘾治疗机构内药物可及性的关联
Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.
作者信息
Knudsen Hannah K, Roman Paul M
机构信息
University of Kentucky.
出版信息
Sociol Focus. 2009;42:133-151. doi: 10.1080/00380237.2009.10571347.
Abstract
Most analyses of racial and ethnic disparities in healthcare focus on individuals rather than organizations. Healthcare organizations may be one mechanism that produces disparities if the representation of minorities within organizations' patient populations is associated with differential patterns of service delivery. This research considers whether the racial and ethnic composition of addiction treatment centers' caseloads is associated with the likelihood that organizations offer any prescription medications to treat addiction, psychiatric conditions, or pain. Data were collected from 288 publicly-funded substance abuse treatment centers in the US. Logistic regression was used to estimate models of medication availability. The percentage of racial and ethnic minority patients was negatively associated with the odds of medication availability, even after controlling for organizational characteristics and patients' diagnostic characteristics. Future research should continue to investigate how healthcare organizations may produce inequalities in access to high-quality care.
摘要
大多数关于医疗保健中种族和民族差异的分析都侧重于个体而非组织。如果组织患者群体中的少数群体代表性与不同的服务提供模式相关，那么医疗保健组织可能是产生差异的一种机制。本研究探讨成瘾治疗中心病例负荷的种族和民族构成是否与组织提供任何用于治疗成瘾、精神疾病或疼痛的处方药的可能性相关。数据收集自美国288家由公共资金资助的药物滥用治疗中心。采用逻辑回归来估计药物可及性模型。即使在控制了组织特征和患者的诊断特征之后，种族和少数民族患者的百分比与药物可及性的几率呈负相关。未来的研究应继续调查医疗保健组织如何可能在获得高质量护理方面产生不平等。
相似文献
1
Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.种族和族裔构成与成瘾治疗机构内药物可及性的关联
Sociol Focus. 2009;42:133-151. doi: 10.1080/00380237.2009.10571347.
2
Racial and ethnic disparities in SSRI availability in substance abuse treatment.物质滥用治疗中选择性5-羟色胺再摄取抑制剂（SSRI）可及性方面的种族和族裔差异。
Psychiatr Serv. 2007 Jan;58(1):55-62. doi: 10.1176/ps.2007.58.1.55.
6
Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizations.促进因素和障碍，以使用药物在公共资助的成瘾治疗组织。
J Addict Med. 2010 Jun;4(2):99-107. doi: 10.1097/ADM.0b013e3181b41a32.
7
Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence.医疗保险D部分综合药物审查对药物依从性方面种族和民族差异的影响。
Am Health Drug Benefits. 2021 Sep;14(3):101-109.
8
Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.美国公共和私人资助的治疗项目在获得治疗物质使用障碍的医生和药物方面的差异。
J Stud Alcohol Drugs. 2013 Mar;74(2):258-65. doi: 10.15288/jsad.2013.74.258.
9
Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.医疗保险受益人群中药物-药物相互作用衡量指标相关的种族和民族差异。
J Am Pharm Assoc (2003). 2022 Jan-Feb;62(1):142-149. doi: 10.1016/j.japh.2021.08.023. Epub 2021 Aug 25.
10
Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups.《平价医疗法案》中药物治疗管理资格标准对不同种族和族裔群体的潜在健康影响。
J Manag Care Spec Pharm. 2015 Nov;21(11):993-1003. doi: 10.18553/jmcp.2015.21.11.993.
引用本文的文献
1
Receipt of medications for opioid use disorders among veterans by race/ethnicity and legal involvement: an observational study of electronic health records.按种族/民族和法律参与情况划分的退伍军人阿片类药物使用障碍药物接收情况：一项电子健康记录观察性研究
Health Justice. 2025 Apr 29;13(1):28. doi: 10.1186/s40352-025-00336-6.
2
Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.与阿片类药物使用污名相关的个体、人际和邻里措施：来自全国代表性调查的证据。
Soc Sci Med. 2022 Jul;305:115034. doi: 10.1016/j.socscimed.2022.115034. Epub 2022 May 14.
3
The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia.平价医疗法案与阿片类药物危机核心地带：来自西弗吉尼亚州的证据。
Health Aff (Millwood). 2019 Apr;38(4):633-642. doi: 10.1377/hlthaff.2018.05049.
4
Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care.美国阿片类药物流行中的种族偏见：系统性偏见历史回顾及其对医疗的影响
Cureus. 2018 Dec 14;10(12):e3733. doi: 10.7759/cureus.3733.
5
Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.多州医疗补助参保者样本中阿片类药物使用障碍患者丁丙诺啡治疗中断的风险因素。
J Subst Abuse Treat. 2018 Dec;95:9-17. doi: 10.1016/j.jsat.2018.09.001. Epub 2018 Sep 7.
6
Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample.美国全国样本中阿片类激动剂治疗阿片类物质使用障碍的种族和民族差异。
Drug Alcohol Depend. 2017 Sep 1;178:512-518. doi: 10.1016/j.drugalcdep.2017.06.009. Epub 2017 Jul 11.
7
Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.基层医疗实践中的阿片类药物成瘾和滥用：美沙酮和丁丙诺啡作为治疗选择的比较。
J Natl Med Assoc. 2012 Jul-Aug;104(7-8):342-50. doi: 10.1016/s0027-9684(15)30175-9.
8
Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.药物滥用治疗领域的医务人员：了解他们在公共资助治疗机构中的就业情况。
J Subst Abuse Treat. 2012 Sep;43(2):152-60. doi: 10.1016/j.jsat.2011.12.003. Epub 2012 Feb 1.
9
Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.对国家政策环境的认知与药物治疗物质使用障碍的采用。
Psychiatr Serv. 2012 Jan;63(1):19-25. doi: 10.1176/appi.ps.201100034.
10
Counselor attitudes toward the use of motivational incentives in addiction treatment.咨询师对在成瘾治疗中使用动机激励的态度。
Am J Addict. 2010 Nov-Dec;19(6):496-503. doi: 10.1111/j.1521-0391.2010.00081.x. Epub 2010 Sep 21.
本文引用的文献
1
Antidepressant prescribing patterns: a comparison of blacks and whites in a medicaid population.抗抑郁药处方模式：医疗补助人群中黑人和白人的比较。
Clin Drug Investig. 1998;16(2):135-40. doi: 10.2165/00044011-199816020-00006.
2
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration.初始严重程度与抗抑郁药疗效：对提交给美国食品药品监督管理局的数据进行的荟萃分析。
PLoS Med. 2008 Feb;5(2):e45. doi: 10.1371/journal.pmed.0050045.
3
Selective publication of antidepressant trials and its influence on apparent efficacy.抗抑郁药物试验的选择性发表及其对表面疗效的影响。
N Engl J Med. 2008 Jan 17;358(3):252-60. doi: 10.1056/NEJMsa065779.
4
Differences in quality between dental practices associated with race and income mix of patients.与患者种族和收入构成相关的牙科诊所之间的质量差异。
J Health Care Poor Underserved. 2007 Nov;18(4):847-67. doi: 10.1353/hpu.2007.0095.
5
Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers.不同时间采用纳曲酮的组织层面预测因素：私立物质使用障碍治疗中心的情况
J Stud Alcohol Drugs. 2007 Nov;68(6):852-61. doi: 10.15288/jsad.2007.68.852.
6
Are racial disparities in alcohol treatment completion associated with racial differences in treatment modality entry? Comparison of outpatient treatment and residential treatment in Los Angeles County, 1998 to 2000.酒精治疗完成率方面的种族差异是否与治疗方式选择上的种族差异有关？1998年至2000年洛杉矶县门诊治疗与住院治疗的比较。
Alcohol Clin Exp Res. 2007 Nov;31(11):1920-6. doi: 10.1111/j.1530-0277.2007.00515.x. Epub 2007 Sep 26.
7
Treatment programs in the National Drug Abuse Treatment Clinical Trials Network.国家药物滥用治疗临床试验网络中的治疗项目。
Drug Alcohol Depend. 2008 Jan 1;92(1-3):200-7. doi: 10.1016/j.drugalcdep.2007.08.004. Epub 2007 Sep 17.
8
Separate and unequal: racial segregation and disparities in quality across U.S. nursing homes.隔离且不平等：美国疗养院中的种族隔离与质量差异
Health Aff (Millwood). 2007 Sep-Oct;26(5):1448-58. doi: 10.1377/hlthaff.26.5.1448.
9
Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996.1996年高效抗逆转录病毒疗法引入前后美国黑人和白人的艾滋病毒死亡率。
Am J Public Health. 2007 Oct;97(10):1884-92. doi: 10.2105/AJPH.2005.081489. Epub 2007 Aug 29.
10
Racial segregation and differential outcomes in hospital care.医院护理中的种族隔离与差异化结果。
West J Nurs Res. 2007 Oct;29(6):739-57. doi: 10.1177/0193945907303167. Epub 2007 Jul 13.
Zotero 插件